Related Experiment Video
Updated: Feb 1, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate
Lorenzo Galluzzi1,2,3, Guido Kroemer4,5,6,7,8,9,10
1Department of Radiation Oncology, Weill Cornell Medical College, New York, US.
Abstract:
Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncometabolite with robust epigenetic effects. Recent data indicate that R-2-HG released by malignant cells can accumulate in the extracellular space and be taken up by T lymphocytes, ultimately compromising their capacity to mediate anticancer immune responses. Thus, R-2-HG drives oncogenesis and tumor progression not only as a cancer cell-autonomous epigenetic modifier, but also as an immunosuppressive metabolite. Chemical inhibitors of mutant IDH1 and IDH2, which currently are under clinical evaluation, may therefore mediate dual anticancer effects by targeting cancer cells and, at the same time, relieving R-2-HG-mediated immunosuppression.
Insights
Mutations in isocitrate dehydrogenase (IDH) enzymes drive cancer by producing the oncometabolite R-2-hydroxyglutarate (R-2-HG). This metabolite also suppresses anti-cancer T cell responses, suggesting dual therapeutic potential for IDH inhibitors.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1 (IDH1) and isocitrate dehydrogenase (NADP(+)) 2 (IDH2) are key drivers in acute myeloid leukemia and glioma.
- These mutations lead to the production of the oncometabolite R-2-hydroxyglutarate (R-2-HG), which has significant epigenetic effects within cancer cells.
Discussion:
- Extracellular R-2-HG, released by malignant cells, can be absorbed by T lymphocytes.
- This uptake impairs the ability of T lymphocytes to mount effective anti-cancer immune responses, highlighting R-2-HG's immunosuppressive role.
- R-2-HG contributes to oncogenesis and tumor progression through both cell-autonomous epigenetic modification and systemic immunosuppression.
Key Insights:
- Mutant IDH enzymes produce R-2-HG, a metabolite that promotes cancer and suppresses anti-tumor immunity.
- R-2-HG acts as an oncometabolite affecting cancer cell epigenetics and also as an immunosuppressive factor.
- Targeting mutant IDH1 and IDH2 offers a dual therapeutic strategy against cancer and its associated immune suppression.
Outlook:
- Clinical evaluation of chemical inhibitors targeting mutant IDH1 and IDH2 is ongoing.
- These inhibitors hold promise for dual therapeutic effects: directly impacting cancer cells and alleviating R-2-HG-induced immunosuppression.
- Future research may focus on optimizing these inhibitors for comprehensive cancer treatment by addressing both oncogenic and immunosuppressive mechanisms.
Related Concept Videos
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Biological Effects of Radiation
2° Amines to N-Nitrosamines: Reaction with NaNO2
Effects of feedback
Feedback significantly modifies the gain of a control system. The gain of a system without feedback is altered by a factor of one plus GH, where G represents...

